Who Paid My Doc
A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T
Research payments
$4,743,566
Through program year 2025, $4,743,566 in research payments was reported against A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T, across 721 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $63,628 | 9 |
| 2024 | Research | $566,868 | 189 |
| 2023 | Research | $2,629,854 | 302 |
| 2022 | Research | $1,282,824 | 191 |
| 2021 | Research | $200,393 | 30 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Holly Lim West Covina, CA Named on 37 payments
- Jose Diaz Los Angeles, CA Named on 26 payments
- Joseph Domachowske Syracuse, NY Named on 22 payments
- Juan Mocega Huntington Park, CA Named on 17 payments
- Christine Turley Charlotte, NC Named on 16 payments
- Carmen Deseda San Juan, PR Named on 15 payments
- Sherri Casey Covington, LA Named on 13 payments
- Julie Shepard Dayton, OH Named on 13 payments
- Michael Bornstein Sugar Land, TX Named on 12 payments
- Keith Pulvermacher Marshfield, WI Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.